Is BioAge Labs, Inc (BIOA) overvalued? · rev $9.0M
BioAge Labs, Inc (BIOA) is a drug manufacturers - specialty & generic company listed on US.
This page asks whether BioAge Labs, Inc (BIOA) looks expensive on cached numbers — not a short thesis.
Latest reported BIOA revenue for 2025-12-31 was $9.0M. Net income was -$80.6M. BIOA currently screens at market cap $697.9M.
BIOA currently screens at market cap $697.9M. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next BIOA 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the BIOA stock page for the full model, not this heading.
Not investment advice.